Literature DB >> 25816748

Triggering receptor expressed on myeloid cells-2 is involved in prion-induced microglial activation but does not contribute to prion pathogenesis in mouse brains.

Caihong Zhu1, Uli S Herrmann2, Bei Li2, Irina Abakumova2, Rita Moos2, Petra Schwarz2, Elisabeth J Rushing2, Marco Colonna3, Adriano Aguzzi4.   

Abstract

Dysfunctional variants of the innate immune cell surface receptor TREM2 (triggering receptor expressed on myeloid cells-2) were identified as major genetic risk factors for Alzheimer's disease and other neurodegenerative conditions. Here we assessed a possible involvement of TREM2 in prion disease. We report that TREM2 expression by microglia is significantly up-regulated upon prion infection. However, depletion of TREM2 did not affect disease incubation time and survival after intracerebral prion infection. Interestingly, markers of microglial activation were attenuated in prion-infected TREM2(-/-) mice, suggesting an involvement of TREM2 in prion-induced microglial activation. Further phenotype profiling of microglia revealed that TREM2 deficiency did not change microglial phenotypes. We conclude that TREM2 is involved in prion-induced microglial activation but does not noticeably modulate the pathogenesis of experimental prion infections.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Microglial activation; Neuroinflammation; Pathogenesis; Prion disease; TREM2

Mesh:

Substances:

Year:  2015        PMID: 25816748     DOI: 10.1016/j.neurobiolaging.2015.02.019

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  22 in total

Review 1.  Microglia in prion diseases.

Authors:  Adriano Aguzzi; Caihong Zhu
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

2.  Region-specific glial homeostatic signature in prion diseases is replaced by a uniform neuroinflammation signature, common for brain regions and prion strains with different cell tropism.

Authors:  Natallia Makarava; Jennifer Chen-Yu Chang; Kara Molesworth; Ilia V Baskakov
Journal:  Neurobiol Dis       Date:  2020-01-27       Impact factor: 5.996

3.  A roadmap for investigating the role of the prion protein in depression associated with neurodegenerative disease.

Authors:  Danielle Beckman; Rafael Linden
Journal:  Prion       Date:  2016-03-03       Impact factor: 3.931

Review 4.  Let's make microglia great again in neurodegenerative disorders.

Authors:  Marie-Victoire Guillot-Sestier; Terrence Town
Journal:  J Neural Transm (Vienna)       Date:  2017-10-12       Impact factor: 3.575

5.  Activation of microglia by retroviral infection correlates with transient clearance of prions from the brain but does not change incubation time.

Authors:  Christiane Muth; Katharina Schröck; Charlotte Madore; Kristin Hartmann; Zain Fanek; Oleg Butovsky; Markus Glatzel; Susanne Krasemann
Journal:  Brain Pathol       Date:  2016-11-21       Impact factor: 6.508

Review 6.  TREM2-Ligand Interactions in Health and Disease.

Authors:  Daniel L Kober; Tom J Brett
Journal:  J Mol Biol       Date:  2017-04-19       Impact factor: 5.469

7.  The role of macrophage scavenger receptor 1 (Msr1) in prion pathogenesis.

Authors:  Bei Li; Meiling Chen; Adriano Aguzzi; Caihong Zhu
Journal:  J Mol Med (Berl)       Date:  2021-03-23       Impact factor: 4.599

Review 8.  The Role of Microglia in Prion Diseases: A Paradigm of Functional Diversity.

Authors:  Juliane Obst; Emilie Simon; Renzo Mancuso; Diego Gomez-Nicola
Journal:  Front Aging Neurosci       Date:  2017-06-23       Impact factor: 5.750

9.  Over-Expressed Pathogenic miRNAs in Alzheimer's Disease (AD) and Prion Disease (PrD) Drive Deficits in TREM2-Mediated Aβ42 Peptide Clearance.

Authors:  Yuhai Zhao; Vivian Jaber; Walter J Lukiw
Journal:  Front Aging Neurosci       Date:  2016-06-14       Impact factor: 5.750

Review 10.  TREM2 in Neurodegenerative Diseases.

Authors:  Taylor R Jay; Victoria E von Saucken; Gary E Landreth
Journal:  Mol Neurodegener       Date:  2017-08-02       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.